Drug Information Association Logo
Corporate Tagline

DIA Adaptive Designs in Clinical Trials: Overcoming Persistent Barriers

Nov 29 2012 8:30AM - Nov 30 2012 4:30PM | Hyatt Regency Washington on Capitol Hill 400 New Jersey Ave NW, Washington, DC 20001-2097 USA

« Back to Listing

Overview 

Clinical trials designed with adaptive features have great potential to result in more efficient decision making within a drug development program, and these potential benefi ts have been recognized by FDA, as expressed in the 2010 draft guidance on Adaptive Design Clinical Trials for Drugs and Biologics. Surveys of adaptive trials designed or conducted in 2008, and again in 2011, with medium to large pharmaceutical companies and CROs have identified barriers to the implementation of these designs. Some barriers have been reduced over time, such as availability of statistical tools and flexible randomization and drug supply systems. Others persist, such as education, change management, pre-planning and simulation, and perceptions of regulatory acceptance.

The goal of this conference is to provide a forum to examine persistent barriers to the use of adaptive design approaches in clinical trials. Recommendations to address these and other barriers will be discussed in an interactive format and within the framework of practical approaches and best practices for conducting adaptive design trials.


Featuring a joint session with the co-located meeting Data Monitoring Committees: Best Practices and Future Directions

Featured Topics 

  • Industry experience to date: review of 2008 and 2011 surveys
  • FDA, CDER experience to date, pre and post guidance
  • Learning from FDA, Center for Devices
  • Considerations for DMCs when adaptive designs are utilized
  • Adaptive design approaches for confi rmatory trials
  • Case studies in the confi rmatory setting
  • Adaptive design approaches in the exploratory setting
  • Case studies in the exploratory setting
  • Importance of trial simulation
  • Learning from the ADAPT-IT grant (Adaptive Designs Accelerating Promising Trials Into Treatments)

Who Should Attend 

Pharmaceutical, academic and government senior-level professionals and decision-makers involved in drug development and working in:

  • Academic health centers/Investigator sites
  • Clinical research & development
  • Data Management
  • Modeling & Simulation
  • Pharmacometrics
  • Project management
  • Regulatory affairs/operations
  • Statistics

Learning Objectives 

At the conclusion of this conference, participants should be able to:

  • Recognize the benefits and issues with the use of adaptive trials
  • Discuss the industry experience to date relative to designing and implementing adaptive trials
  • Recognize the progress that has been made in adaptive designs
  • Identify persistent barriers to the use of AD approaches in clinical trials
  • Discuss answers for solutions to barriers they may be encountering

Special Offers 

Group Discounts Available!  Register 3 and Get the 4th FREE!

Hotel & Travel 

TRAVEL AND HOTEL
Hyatt Regency Washington on Capitol Hill
A limited number of rooms are available at the reduced rate shown below (DIA rate is guaranteed until November 7, 2012, or until room block is filled). Attendees must make their own hotel reservations.

Standard Room Rate $199

Address: 400 New Jersey Avenue, NW Washington, DC 20001
Phone: +1.202.737.1234

The most convenient airport is Ronald Reagan National and attendees should make both airline and hotel reservations as early as possible.

Contact Information 

Registration Questions
Marilyn Ginsberg, Customer Service Associate
Phone +1.215.442.6135
Fax +1.215.442.6199
Marilyn.Ginsberg@diahome.org

Agenda and Event Details
Constance Burnett, Content Lead
Phone +1.215.293.5800
Fax +1.215.442.6199
Constance.Burnett@diahome.org

Logistical Questions
Benjamin Zaitz, Event Planner
Phone +1.215.293.5803
Fax +1.215.442.6199
Benjamin.Zaitz@diahome.org

Tabletop Exhibit Information
Shannon Lewis, Exhibits Associate
Phone +1.215.442.6149
Fax +1.215.442.6199
Shannon.Lewis@diahome.org

Continuing Education 

Drug Information Association has been accredited as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102.

As an IACET Authorized Provider, Drug Information Association offers CEUs for its programs that qualify under the ANSI/IACET Standard. Drug Information Association is authorized by IACET to offer 1.4 CEUs for this program. Participants must attend the entire program in order to be able to receive an IACET statement of credit. No partial credit will be awarded.

CERTIFICATE PROGRAM
This program is part of DIA’s Certificate Program and is awarded the following.
• Clinical Research Certificate Program: X Elective Units each

For more information go to www.diahome.org/certificateprograms

Name Credit Type Max Credits CEU
DIA Adaptive Designs in Clinical Trials IACET 13.50 1.400

Disclosure Policy:

It is DIA policy that anyone in a position to control the content of a continuing education activity must disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and/or the educational activity, and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. Disclosure statements will be included in the course materials.

Statement of Credit:

If you would like to receive a statement of credit, you must attend the program and tutorial(s), if applicable, sign-in at the DIA registration desk each day of the program, and complete the on-line credit request process through DIA’s My Transcript. To access My Transcript, please go to www.diahome.org, select “Login to My DIA” and you will be prompted for your user ID and password. Select “My Transcript” (left side bar) and “Credit Request” to process your credit request. Participants will be able to download a statement of credit upon successful submission of the credit request. My Transcript will be available for credit requests on Friday, December 14.

To view DIA’s Grievance Policy, please visit the CE page on DIA’s website at www.diahome.org

Program Committee 

Previous Next

Agenda  

Day 1 Thursday, November 29, 2012

  • 8:30AM - 9:00AM

    Welcome and Opening Remarks

    Speaker(s):

    • Brenda L. Gaydos, PhD
      Research Fellow, Advance Analytics; Head of Clinical Trial Optimization
      Eli Lilly and Company, United States
    • Gregory Campbell, PhD
      Director, Division of Biostatistics, CDRH
      FDA, United States
  • 9:00AM - 10:30AM

    Session 1: Where Are We Today With Adaptive Designs?


    Session Chair(s):

    • Alex Dmitrienko, PhD
      Executive Director, Center for Statistics in Drug Development
      Quintiles Inc., United States
    • Telba Irony, PhD
      Chief, Biostatistics: General Surgical Devices Branch, CDRH
      FDA, United States

    An overview of the experiences gained to date with adaptive designs will be provided from the prospective of industry and FDA across CDER, DBER, and CDRH. The results of a recent survey conducted by the DIA ADSWG will be shared and compared to a similar survey conducted in 2008. The survey assessed the perception and use of adaptive designs, and identified persistent barriers.

    Speaker(s):

    • Session Presenter
      Li Chen, PhD
      Director, Biostatistics
      Amgen Inc., United States
    • Session Presenter
      Sue-Jane Wang, PhD,MA,MS
      Assoc. Dir., Adaptive Design & Pharmacogenomics, OB, OTS, CDER
      FDA, United States
    • Session Presenter
      Yonghong Gao, PhD
      Mathematical Statistician, Division of Biostatistics, CDRH
      FDA, United States
    • Session Presenter
      Estelle Russek-Cohen, PhD
      Acting Division Director, Division of Biostatistics, OBE, CBER
      FDA, United States
  • 11:00AM - 12:30PM

    Session 2: Overcoming Persistent Barriers


    Session Chair(s):

    • Michael Krams, MD,PhD
      Vice President, Neurology and Franchise Head for CNS
      Johnson & Johnson, United States
    • Amelia Dale Horne, DrPH
      Chief, Vaccine Evaluation Branch
      FDA, United States

    Four persistent barriers were identified from the DIA ADSWG survey: education, change management, planning, and risk of regulatory acceptance. This session will address potential solutions to these barriers. Two industry speakers will address education, change management and planning. To address the risk of regulatory acceptance, a FDA panel will follow with representatives from different offices and divisions. Each panel member will briefly present on experiences within their division prior to taking questions from the audience.

    Speaker(s):

    • Session Presenter
      Vladimir Dragalin, PhD
      Senior Vice President, Clinical Trial Innovation Strategies
      Aptiv Solutions, United States
    • Session Presenter
      Brenda L. Gaydos, PhD
      Research Fellow, Advance Analytics; Head of Clinical Trial Optimization
      Eli Lilly and Company, United States
    • Regulatory Panel Discussion - Session Panelist
      Gregory Campbell, PhD
      Director, Division of Biostatistics, CDRH
      FDA, United States
    • Session Panelist
      Daphne Lin, PhD
      Acting Division Director
      FDA, United States
    • Session Panelist
      Rajeshwari Sridhara, PhD
      Director, Division of Biometric V, Office of Biostatistics, OTS, CDER
      FDA, United States
    • Session Panelist
      John Scott, PhD
      Acting Deputy Director, Division of Biostatistics, OBE, CBER
      FDA, United States
  • 1:30PM - 3:00PM

    Session 3: Sample Size Re-estimation in the Confirmatory Setting


    Session Chair(s):

    • Inna T. Perevozskaya, PhD,MS
      Director, Statistical Research and Consulting Center
      Pfizer Inc., United States
    • Min A. Lin, PhD
      Visiting Scientist, Division of Biostatistics, OBE, CBER
      FDA, United States

    This session will discuss the use of sample-size re-estimation (SSR) in the confirmatory setting from a strategy, operational and regulatory perspective. Representatives from industry will present motivating examples to illustrate why SSR is preferable in some cases to a group sequential design, provide operational issues and solutions, and raise the discussion on whether SSR should be considered as a well understood method. The session will conclude with a presentation on the regulatory experience.

    Speaker(s):

    • Session Presenter
      William R. Prucka, PhD
      Senior Research Scientist
      Eli Lilly & Company, United States
    • Session Presenter
      Olga V Marchenko, PhD,MS
      Vice President, Center for Statistics in Drug Development Innovation
      Quintiles, United States
    • Session Presenter
      Keaven Anderson, PhD
      Executive Director,Statistics: Late Stage Development
      Merck Research Laboratories, United States
    • Session Presenter
      Peiling Yang, PhD
      Team Lead, Division of Biometrics I, Office of Biostatistics, OTS, CDER
      FDA, United States
    • Session Presenter
      Thomas P. Laughren, MD
      Director, Division of Psychiatry Products, ODEI, CDER
      FDA, United States
  • 3:30PM - 5:30PM

    Joint Session 4: Role of DMC in Adaptive Designs


    Session Chair(s):

    • Lisa M. LaVange, PhD
      Director, Office of Biostatistics, Office of Translational Science, CDER
      FDA, United States

    Adaptive designs present additional challenges to the role of a DMC. The primary role of a DMC is patient safety. Yet some interim decisions in an adaptive design, such as dose selection, may lie in a domain which is traditionally a sponsor responsibility. Concerns about restricting access to interim results need to be addressed, and operational bias needs to be minimized. In this session, views will be presented from the sponsor and DMC member perspective. Case studies will be discussed followed by a panel discussion.

    Speaker(s):

    • Session Presenter
      David L. DeMets, PhD
      Professor, Department of Biostatistics & Medical Informatics
      University of Wisconsin, United States
    • Session Presenter
      Paul P. Gallo, PhD
      Biometrical Fellow
      Novartis Pharmaceuticals Corporation, United States
    • Case Study 1: A Seamless 2/3 Design
      Brenda L. Gaydos, PhD
      Research Fellow, Advance Analytics; Head of Clinical Trial Optimization
      Eli Lilly and Company, United States
    • Case Study 1: A Seamless 2/3 Design
      Raymond Carroll, PhD
      Distinguished Professor
      Texas A&M University, United States
    • Panel Discussion - Moderator:
      Lisa M. LaVange, PhD
      Director, Office of Biostatistics, Office of Translational Science, CDER
      FDA, United States
    • Panelist
      Gregory Campbell, PhD
      Director, Division of Biostatistics, CDRH
      FDA, United States
    • Panelist
      Bram Zuckerman, MD
      Director, CDRH
      FDA, United States
    • Panelist
      John J. Orloff, MD
      Senior Vice President; Chief Medical Officer
      Novartis Pharmaceuticals Corporation, United States
    • Panelist
      David L. DeMets, PhD
      Professor, Department of Biostatistics & Medical Informatics
      University of Wisconsin, United States
    • Panelist
      Janet Turk Wittes, PhD
      President
      Statistics Collaborative Inc., United States
    • Panelist
      Marc K. Walton, MD,PhD
      Associate Director, Translational Medicine, Office of Translation Sciences, CDER
      FDA, United States

Day 2 Friday, November 30, 2012

  • 8:30AM - 10:00AM

    Session 5: Importance of Trial Simulation


    Session Chair(s):

    • Gerry W. Gray, PhD
      Deputy Director, Division of Biostatistics, CDRH
      FDA, United States
    • Nitin R. Patel, PhD,MBA
      Founder, Chairman and Chief Technology Officer
      Cytel Inc., United States

    Trial simulation can improve design by providing quantitative estimates of a study’s operating characteristics under a more realistic set of a therapies performance and trial conduct scenarios. If an adaptive design is one of the alternatives under consideration, simulations are typically required to understand the impact of interim decision on trial conduct and on the final analysis. In this session, the importance of using trial simulation in traditional fixed designs as well as in adaptive designs will be demonstrated. The issue of utilizing simulation to justify control of the type 1 error rate will be discussed. The session will conclude with a perspective on the use of simulation and Bayesian methods in CDRH.

    Speaker(s):

    • Session Presenter
      J. Kyle Wathen, PhD
      Director
      Janssen Research & Development, LLC, United States
    • Session Presenter
      Scott Berry, PhD
      President and Senior Statistical Scientist
      Berry Consultants, United States
    • Session Presenter
      Andrew Peter Grieve, DrSc,PhD,MSc
      Senior Vice President Clinical Trial Methodology
      Aptiv Solutions, Germany
    • Session Presenter
      Xuefeng Li, PhD
      Mathematical Statistician
      FDA, United States
  • 10:15AM - 11:45AM

    Session 6: Use of Biomarkers in Adaptive Designs


    Session Chair(s):

    • J. Todd Sahlroot, PhD
      Deputy Director, Division of Biometrics II, OB, OTS, CDER
      FDA, United States
    • Eva R Miller, PhD,MS
      Senior Director, Biostatistics and Programming
      Quality Data Services, Inc., United States

    This session will focus on ways in which biomarkers are incorporated into adaptive designs. Confirmatory clinical trials that incorporate biomarker analyses at interim for purposes of sample size re-estimation, while data on the clinical endpoint remains masked, will be discussed. Other topics include adaptive designs in group sequential trials with futility analyses conducted at interim time points that incorporate the correlation between biomarkers and clinical endpoints, comparisons between fixed and adaptive randomization, and Bayesian tools for adaptive enrichment based on biomarkers. The session closes with a regulatory perspective on the use of biomarkers in adaptive designs.

    Speaker(s):

    • Session Presenter
      Emmanuel Zuber, PhD
      Global Head Biostatistics Full Development
      Novartis Pharma AG, Switzerland
    • Session Presenter
      David L. DeMets, PhD
      Professor, Department of Biostatistics & Medical Informatics
      University of Wisconsin, United States
    • Session Presenter
      Robert J. Temple, MD
      Deputy Center Director for Clinical Science, CDER
      FDA, United States
    • Session Presenter
      Mei-Chiung Shih, PhD
      Assistant Professor, Health Research & Policy - Biostatistics
      Stanford University, United States
    • Session Presenter
      Sue-Jane Wang, PhD,MA,MS
      Assoc. Dir., Adaptive Design & Pharmacogenomics, OB, OTS, CDER
      FDA, United States
  • 12:45PM - 2:15PM

    Session 7: Adaptive Design Approaches in the Exploratory Setting


    Session Chair(s):

    • Weili He, PhD
      Director, Biostatistics
      Merck & Co., Inc., United States
    • Kun He, PhD
      Mathematical Statistician
      FDA, United States

    Adaptive designs have a great potential to improve the information value of studies in the exploratory phase of development. In particular, adaptive dose-finding designs provide opportunities to improve the characterization of the dose response more efficiently than a traditional fixed design. In this session, methods and examples of the use of adaptive designs in the exploratory setting will be presented. The session will conclude with a regulatory perspective.

    Speaker(s):

    • Session Presenter
      Jose C. Pinheiro, PhD
      Senior Director, Quantitative Decision Strategies
      Janssen Research & Development, LLC, United States
    • Session Presenter
      Bjoern Bornkamp, PhD,MSc
      Expert Statistical Methodologist - Integrated Information Sciences
      Novartis Pharma AG, Switzerland
    • Session Presenter
      Yili Pritchett, PhD
      Research Fellow; Director, Clinical Statistics
      Abbott Laboratories, United States
    • Session Presenter
      Greg Soon, PhD
      Team Leader, Division of Biometrics IV, OB, OTS, CDER
      FDA, United States
    • Session Presenter
      Shiowjen Lee, PhD
      Statistician, Division of Biostatistics, OBE, CBER
      FDA, United States
  • 2:30PM - 4:30PM

    Session 8: Adaptive Treatment or Population Selection in Confirmatory Setting


    Session Chair(s):

    • Jeff Maca, PhD
      Senior Director, Center for Statistics in Drug Development Innovation
      Quintiles, United States
    • Boguang Zhen, PhD
      Branch Chief, Therapeutics Evaluation Branch, Division of Biostatistics, CBER
      FDA, United States

    Even with a robust phase 2 data package, too much uncertainty may exist at the end of Phase 2 to determine the best dose(s) or patient population to study further in phase 3. Adaptive dose selection and population selection designs enables the investigation of a broader range of variables in Phase 3 while also allowing for a reduction in the time and resources that would be necessary with a fixed design. In this session, statistical methods and case studies will be presented to illustrate the benefits and cautions for these approaches in the confirmatory setting. This session will conclude with a summary wrap-up and panel discussion of next steps based on the 2-day workshop.

    Speaker(s):

    • Session Presenter
      Martin Posch, DrSc,PhD
      Professor of Medical Statistics, Center for Medical Statistics
      Medical University of Vienna, Austria
    • Case Study 1
      Cyrus R. Mehta, PhD
      Founder and President
      Cytel Inc., United States
    • Case Study 2
      Caroline Claire Morgan, PhD
      Director, Business Development
      Cytel Inc., United States
    • Regulatory Perspective
      H. M. James Hung, PhD
      Division Director
      FDA, United States
    • Session Panelist
      Brenda L. Gaydos, PhD
      Research Fellow, Advance Analytics; Head of Clinical Trial Optimization
      Eli Lilly and Company, United States
    • Session Panelist
      Lisa M. LaVange, PhD
      Director, Office of Biostatistics, Office of Translational Science, CDER
      FDA, United States
    • Session Panelist
      Robert J. Temple, MD
      Deputy Center Director for Clinical Science, CDER
      FDA, United States
    • Session Panelist
      David L. DeMets, PhD
      Professor, Department of Biostatistics & Medical Informatics
      University of Wisconsin, United States
    • Session Panelist
      Estelle Russek-Cohen, PhD
      Acting Division Director, Division of Biostatistics, OBE, CBER
      FDA, United States
    • Session Panelist
      Gregory Campbell, PhD
      Director, Division of Biostatistics, CDRH
      FDA, United States

Registration Fees 

Member

Member Academia
$745.00
Member Government
$595.00
Member Standard
$1490.00

Non-Member

NonMember Academia
$920.00
NonMember Government
$770.00
NonMember Standard
$1665.00
Group Discounts

Register three individuals from the same company and receive complimentary registration for a fourth! All four individuals must register and prepay at the same time – no exceptions. DIA will apply the value of the lowest applicable fee to this complimentary registration; it does NOT include fees for optional events or DIA membership. You may substitute group participants of the same membership status at any time; however, administrative fees may be incurred. Group registration is not available online and does not apply to the already-discounted fees for government or charitable nonprofit/academia. To take advantage of this offer, please make a copy of the registration form for EACH of the four registrants from your company. Include the names of all four group registrants on each of the forms and return them together to DIA.

Register Online

CANCELLATION POLICY: All cancellations must be received in writing two weeks before
the start of the event. Administrative fee that will be withheld from refund amount:

  • Member or Nonmember = $200
  • Government or Academia or Nonprofit (Member or Nonmember) = $100
  • Tutorial (if applicable) = $50

Cancellations must be in writing and be received two weeks before the start of the event. Registrants who do not cancel two weeks before the start of the event and do not attend the event will be responsible for the full registration fee. Registrants are responsible for cancelling their own hotel and airline reservations. DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.

Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.

Participants with Disabilities:
Reasonable accommodations will be made available to persons with disabilities who attend an educational activity. Contact the DIA office in writing at least 15 days prior to event to indicate your needs.

« Back to Listing Back To Top